1 / 4

North America Generic Drugs Market Trends, Size, Competitive Analysis and Foreca

North America generic drugs market is estimated to grow at a CAGR of nearly 7.2% during the forecast period. The increasing prevalence of chronic diseases is a major factor in driving the market growth.

Meenoo
Download Presentation

North America Generic Drugs Market Trends, Size, Competitive Analysis and Foreca

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Orion Market Research North America Generic Drugs Market, Size, Share, Analysis Report & Forecast to 2026 To Market: https://www.omrglobal.com/request-sample/north-america-generic-drugs-market Request a Sample of our Report on North America Generic Drugs Company Name: Orion Market Research Contact Person: Mr. Anurag Tiwari Email: info@omrglobal.com Contact no: +91 780-304-0404

  2. North America generic drugs market North America generic drugs market is estimated to grow at a CAGR of nearly 7.2% during the forecast period. Significant initiatives by regulatory authorities to stimulate generic drug approvals are supporting to drive market growth. For instance, in October 2007, the US FDA introduced the Generic Initiative for Value and Efficiency (GIVE). As an initiative, GIVE will utilize existing resources to support the US FDA to advance and streamline the approval process of generic drugs. The initiative is intended to increase the availability of generic drugs. The increasing availability of generic-drug alternatives results in more cost-savings to consumers, as generic drugs cost nearly 30% to 80% lower compared to the brand name drugs. (Get 15% Discount on Buying this Report) A full Report of North America Generic Drugs Market is Available at: https://www.omrglobal.com/industry-reports/north-america-generic-drugs-market In 2019, the US FDA approved a total of over 1,000 generic drug final and tentative approvals. In 2019, the US FDA approvals comprised 107 applications for first generics of drugs that had no generic competition, which includes medicines for the treatment of depression, breast cancer, pulmonary arterial hypertension, seizures, and several infections and 110 complex generic drugs that are harder to develop and usually have lacked competition. The increasing availability of generic drugs will further bring down the cost of generics and thereby will accelerate market growth. To Request a Sample of our Report Market: https://www.omrglobal.com/request-sample/north-america-generic-drugs-market on North America Generic Drugs Scope of the North America Generic Drugs Market Market Coverage •Market number available for 2019-2026 •Base year- 2019 •Forecast period- 2020-2026 •Segment Covered- By Application and Route of Administration •Countries Covered- US and Canada •Competitive Landscape- Mylan N.V., Teva Pharmaceutical Industries Ltd., Lupin Ltd., Novartis International AG, and Sun Pharmaceutical Industries Ltd. Recent Strategic Initiatives in the North America Generic Drugs Market •In October 2020, Teva Pharmaceuticals USA, Inc. declared the availability of the first US FDA- approved generic versions of TRUVADA i and ATRIPLA i tablets. These products, along with over 10 HIV-related drugs are already on the WHO’s Essential Medicines List. By launching these new generic options for HIV treatment, Teva will further increase access to vital therapies and strengthen its position in the generic marketplace. •In April 2020, Cipla Ltd. received the US FDA approval of the first generic of Proventil HFA (albuterol sulfate) metered-dose inhaler, 90 mcg/Inhalation. This is indicated for the treatment or prevention of bronchospasm in patients four years of age and older suffering from reversible obstructive airway disease, as well as the prevention of exercise-induced bronchospasm in this age group. North America Generic Drugs Market-Segmentation By Application

  3. •Cancer •CVD •Musculoskeletal Diseases •Infectious Diseases •Neurology •Diabetes •Others By Route of Administration •Oral •Topical •Injectable •Inhaler North America Generic Drugs Market– Segment by Country •US •Canada Company Profiles •Abbott Laboratories •Amneal Pharmaceuticals LLC •Aurobindo Pharma Ltd. •Baxter International Inc. •Eli Lilly and Co. •Glenmark Pharmaceuticals Ltd. •Lannett Co. Inc. •Lupin Ltd. •Merck & Co., Inc. •Mylan N.V. •Teva Pharmaceutical Industries Ltd. Reasons to Buying From us – 1. We cover more than 15 major industries, further segmented into more than 90 sectors. 2. More than 120 countries are for analysis. 3. Over 100+ paid data sources mined for investigation. 4. Our expert research analysts answer all your questions before and after purchasing your report. For More Customized Data, Request for Report Customization @ https://www.omrglobal.com/report- customization/north-america-generic-drugs-market About Orion Market Research Orion Market Research (OMR) is a market research and consulting company known for its crisp and concise reports. The company is equipped with an experienced team of analysts and consultants. OMR offers quality syndicated research reports, customized research reports, consulting and other research- based services. For More Information, Visit Orion Market Research

  4. Media Contact: Company Name: Orion Market Research Contact Person: Mr. Anurag Tiwari Email: info@omrglobal.com Contact no: +91 7803040404

More Related